PUMA BIOTECHNOLOGY, INC. (24)

Browse by Contract Category

Contracts

Open Market Sale AgreementSM, dated November 4, 2021, by and between Puma Biotechnology, Inc. and Jefferies LLC (Filed With SEC on November 4, 2021)
Fifth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (Filed With SEC on June 17, 2021)
Amendment to Warrant to Purchase Shares of Common Stock of Puma Biotechnology, Inc (Filed With SEC on June 17, 2021)
Amendment No. 3 to the License Agreement, dated February 24, 2021, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 6, 2021)
Termination Agreement, dated February 24, 2021, by and between the Company and CANbridge BIOMED Limited (Filed With SEC on May 6, 2021)
Fourth Amendment to Amended and Restated Loan and Security Agreement, dated February 3, 2021, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on May 6, 2021)
Letter Agreement, dated February 13, 2020, by and between the Company and Jeff J. Ludwig (Filed With SEC on March 1, 2021)
Amendment No. 2 to License Agreement dated October 29, 2020, between the Company and Pfizer Inc (Filed With SEC on March 1, 2021)
Pfizer Letter Agreement dated June 8, 2020, by and between the Company and Pfizer Inc (Filed With SEC on August 6, 2020)
Third Amendment to Amended and Restated Loan and Security Agreement, dated August 5, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on August 6, 2020)
Second Amendment to Amended and Restated Loan and Security Agreement, dated July 6, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on August 6, 2020)
Amended Non-Employee Director Compensation Program (Filed With SEC on May 7, 2020)
First Amendment to Amended and Restated Loan and Security Agreement, dated February 27, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender (Filed With SEC on March 4, 2020)
Second Amendment to the License Agreement, dated November 25, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)
First Amendment to the License Agreement, dated September 17, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on February 28, 2020)
Amendment to the License Agreement, dated December 18, 2019, by and between the Company and Knight Therapeutics, Inc (Filed With SEC on February 28, 2020)
Description of the Company's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 28, 2020)
Amended Non-Employee Director Compensation Program (Filed With SEC on November 7, 2019)
Amended and Restated Loan and Security Agreement, dated June 28, 2019, by and between the Company and Oxford Finance LLC, as collateral agent and lender (Filed With SEC on August 9, 2019)
License Agreement, dated March 29, 2019, by and between the Company and Pierre Fabre Medicament SAS (Filed With SEC on May 10, 2019)
Side Letter Agreement, dated November 19, 2018, between the Company and CANbridge Biomed Limited (as successor in interest to CANbridgepharma Limited) (Filed With SEC on March 1, 2019)
License Agreement, dated January 9, 2019, by and between the Company and Knight Therapeutics Inc (Filed With SEC on March 1, 2019)
Form of Stock Option Grant Notice and Stock Option Agreement, issued pursuant to the 2017 Employment Inducement Incentive Award Plan (Filed With SEC on March 1, 2019)
Form Transition and General Release Agreement by and between Puma Biotechnology, Inc. and Charles R. Eyler (Filed With SEC on February 12, 2019)